|
1
|
Lheureux S, Gourley C, Vergote I and Oza
AM: Epithelial ovarian cancer. Lancet. 393:1240–1253. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Griffiths RW, Zee YK, Evans S, Mitchell
CL, Kumaran GC, Welch RS, Jayson GC, Clamp AR and Hasan J: Outcomes
after multiple lines of chemotherapy for platinum-resistant
epithelial cancers of the ovary, peritoneum, and fallopian tube.
Int J Gynecol Cancer. 21:58–65. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boussios S, Karihtala P, Moschetta M,
Karathanasi A, Sadauskaite A, Rassy E and Pavlidis N: Combined
strategies with poly (ADP-Ribose) polymerase (PARP) inhibitors for
the treatment of ovarian cancer: A literature review. Diagnostics
(Basel). 9:872019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luvero D, Milani A and Ledermann JA:
Treatment options in recurrent ovarian cancer: Latest evidence and
clinical potential. Ther Adv Med Oncol. 6:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang QE, Milum K, Han C, Huang YW, Wani G,
Thomale J and Wani AA: Differential contributory roles of
nucleotide excision and homologous recombination repair for
enhancing cisplatin sensitivity in human ovarian cancer cells. Mol
Cancer. 10:242011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Borst P, Rottenberg S and Jonkers J: How
do real tumors become resistant to cisplatin? Cell Cycle.
7:1353–1359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Norouzi-Barough L, Sarookhani MR, Sharifi
M, Moghbelinejad S, Jangjoo S and Salehi R: Molecular mechanisms of
drug resistance in ovarian cancer. J Cell Physiol. 233:4546–4562.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burdova K, Storchova R, Palek M and
Macurek L: WIP1 promotes homologous recombination and modulates
sensitivity to PARP inhibitors. Cells. 8:12582019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lord CJ and Ashworth A: The DNA damage
response and cancer therapy. Nature. 481:287–294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang QG, Xiong CF and Lv YX: Kin17
facilitates thyroid cancer cell proliferation, migration, and
invasion by activating p38 MAPK signaling pathway. Mol Cell
Biochem. 476:727–739. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
The Cancer Genome Atlas Research Network,
. Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Denis SFB, Miccoli L, Despras E, Frobert
Y, Creminon C and Angulo JF: Ionizing radiation triggers
chromatin-bound kin17 complex formation in human cells. J Biol
Chem. 277:19156–19165. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zeng T, Gao H, Yu P, He H, Ouyang X, Deng
L and Zhang Y: Up-regulation of kin17 is essential for
proliferation of breast cancer. PLoS One. 6:e253432011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Gao H, Gao X, Huang S, Wu K, Yu
X, Yuan K and Zeng T: Elevated expression of Kin17 in cervical
cancer and its association with cancer cell proliferation and
invasion. Int J Gynecol Cancer. 27:628–633. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kou WZ, Xu SL, Wang Y, Wang LW, Wang L,
Chai XY and Hua QL: Expression of Kin17 promotes the proliferation
of hepatocellular carcinoma cells in vitro and in
vivo. Oncol Lett. 8:1190–1194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Huang S, Gao H, Wu K, Ouyang X,
Zhu Z, Yu X and Zeng T: Upregulation of KIN17 is associated with
non-small cell lung cancer invasiveness. Oncol Lett. 13:2274–2280.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu KH, Patterson AP, Wang L, Marquez RT,
Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I,
et al: Selection of potential markers for epithelial ovarian cancer
with gene expression arrays and recursive descent partition
analysis. Clin Cancer Res. 10:3291–3300. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Anglesio MS, Arnold JM, George J, Tinker
AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S,
Traficante N, et al: Mutation of ERBB2 provides a novel alternative
mechanism for the ubiquitous activation of RAS-MAPK in ovarian
serous low malignant potential tumors. Mol Cancer Res. 6:1678–1690.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Györffy B, Surowiak P, Kiesslich O,
Denkert C, Schäfer R, Dietel M and Lage H: Gene expression
profiling of 30 cancer cell lines predicts resistance towards 11
anticancer drugs at clinically achieved concentrations. Int J
Cancer. 118:1699–1712. 2006. View Article : Google Scholar
|
|
23
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Heintz AP, Odicino F, Maisonneuve P, Quinn
MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U:
Carcinoma of the ovary. FIGO 26th annual report on the results of
treatment in gynecological cancer. Int J Gynaecol Obstet. 95 (Suppl
1):S161–S192. 2006. View Article : Google Scholar
|
|
25
|
Kong D, Chen J, Sun X, Lin Y, Du Y, Huang
D, Cheng H, He P, Yang L, Wu S, et al: GRIM-19 over-expression
represses the proliferation and invasion of orthotopically
implanted hepatocarcinoma tumors associated with downregulation of
Stat3 signaling. Biosci Trends. 13:342–350. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kannouche P, Mauffrey P, Pinon-Lataillade
G, Mattei MG, Sarasin A, Daya-Grosjean L and Angulo JF: Molecular
cloning and characterization of the human KIN17 cDNA encoding a
component of the UVC response that is conserved among metazoans.
Carcinogenesis. 21:1701–1710. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Despras E, Miccoli L, Créminon C,
Rouillard D, Angulo JF and Biard DS: Depletion of KIN17, a human
DNA replication protein, increases the radiosensitivity of RKO
cells. Radiat Res. 159:748–758. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ovarian cancer. Nat Rev Dis Primers.
2:160622016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Haynes B, Saadat N, Myung B and Shekhar
MP: Crosstalk between translesion synthesis, Fanconi anemia
network, and homologous recombination repair pathways in
interstrand DNA crosslink repair and development of
chemoresistance. Mutat Res Rev Mutat Res. 763:258–266. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Prat J: New insights into ovarian cancer
pathology. Ann Oncol. 23 (Suppl 10):x111–x117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Doufekas K and Olaitan A: Clinical
epidemiology of epithelial ovarian cancer in the UK. Int J Womens
Health. 6:537–545. 2014.PubMed/NCBI
|
|
33
|
Chen H, Lisby M and Symington LS: RPA
coordinates DNA end resection and prevents formation of DNA
hairpins. Mol Cell. 50:589–600. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xue Z, Zhu X and Teng Y: Long non-coding
RNA CASC2 inhibits progression and predicts favorable prognosis in
epithelial ovarian cancer. Mol Med Rep. 18:5173–5181.
2018.PubMed/NCBI
|
